Company / Operating Cash Flow
FATE THERAPEUTICS INC Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$122.9M
FY2025
5-year range
-$248.2M / -$39.2M
FY2021-FY2025
Trend
+7.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow has fluctuated over the past 10 years, ranging from -$248M in FY2023 to -$18M in FY2017.
Based on SEC 10-K filings.
-$123M in FY2025.
Improved from -$248M to -$123M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow increased 7.1% year-over-year.
- Peak operating cash flow was recorded in FY2017.
- Lowest operating cash flow in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 632.81 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$122.9M | +7.1% |
| FY2024 | -$132.3M | +46.7% |
| FY2023 | -$248.2M | -532.7% |
| FY2022 | -$39.2M | +52.8% |
| FY2021 | -$83.2M | -115.2% |
| FY2020 | -$38.6M | -5.0% |
| FY2019 | -$36.8M | -23.5% |
| FY2018 | -$29.8M | -62.1% |
| FY2017 | -$18.4M | +17.9% |
| FY2016 | -$22.4M | -45.8% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026